Results 11 to 20 of about 1,634 (131)

Evaluation of medication treatment for Alzheimer's disease on clinical evidence [PDF]

open access: yes, 2014
Objective To formulate the best treatment plan for Alzheimer's disease patients by evaluating the therapeutic efficacy and side effect of various evidence-based programs.
Ling LIU   +3 more
core   +2 more sources

Research progress on the relationship between axonal transport dysfunction in neuronal cells and Alzheimer’s disease [PDF]

open access: yes, 2022
Alzheimer’s disease is known as one of the “top ten killers in the world”. Due to lack of effective therapy at present, early pathological changes have captivated widespread attention.
Yu Minghui, Xue Ao, Xu Hongdan, Wang Yan, Lin Xue, Yang Bo, Sun Huifeng, Zhang Ning
core   +1 more source

PT109改善链脲佐菌素诱导的散发性阿尔茨海默病小鼠认知功能障碍的作用及机制 [PDF]

open access: yes, 2021
目的观察PT109能否改善侧脑室注射链脲佐菌素(icv-STZ)诱导的散发性AD小鼠模型的认知功能障碍并对其机制进行初步探讨。方法32只7周龄雄性C57BL/6小鼠分为正常组(7只)、模型组(7只)、PT109低剂量组(9只)、PT109高剂量组(9只)。将STZ于第1和3天注射入小鼠侧脑室建立散发性阿尔茨海默病小鼠模型;(3mg/kg,每个注射位点5μL)造模后,分别腹腔注射PT109(30、100 mg·kg-1·d-1),2周后通过Morris水迷宫和避暗实验评价小鼠学习记忆能力;随后通过免疫荧光、
侯加卫   +5 more
core   +1 more source

11C-PIB PET在阿尔茨海默病中的应用进展

open access: yesZhongguo shiyan zhenduanxue, 2022
阿尔茨海默病(AD)是一种进行性认知功能障碍为核心的中枢神经系统变性病[1],患者不仅存在脑组织结构和功能的异常,还有脑分子代谢改变。阿尔茨海默病生物标志物是评估疾病病理生理学特征的客观量化指标[2],近年来NIA-AA[3]提出AT(N)研究框架,其将生物标志物β-淀粉样蛋白(Aβ)沉积(A)、
李佳霖   +5 more
doaj  

Trisomy 21-induced Dysregulation of Microglial Homeostasis in Alzheimer’s Brains is Mediated by USP25 [PDF]

open access: yes, 2021
阿尔茨海默病(Alzheimer’s disease, AD)是一种最为常见的与记忆、认知能力退化相关的渐进性神经退行性疾病。唐氏综合征(Down’s syndrome, DS)是早发型阿尔茨海默病的一个重要风险因素,作为最常见的智力障碍遗传疾病,厦门大学医学院神经科学研究所王鑫教授团队揭示了治疗阿尔茨海默病和唐氏综合征新的治疗靶点,并且在小鼠模型上利用USP25小分子抑制剂成功地改善了阿尔茨海默病小鼠的认知功能,缓解了神经退行性病变的病理进程。该研究工作由王鑫教授指导完成 ...
Anjie Di   +35 more
core   +1 more source

Research progress in the effect of nutritional intervention on cognitive impairment related to Alzheimer's disease [PDF]

open access: yes, 2023
Alzheimer's disease (AD) is an age-related neurodegenerative disease with insidious onset and slow progression. The progression of AD from only brain pathological changes to clinically identifiable cognitive changes is affected by a variety of ...
HUANG Gaozhong, JIANG Xinting
core   +1 more source

CRMP2衍生的TAT-CBD3多肽对阿尔茨海默病神经元的保护作用

open access: yesZhongguo shiyan zhenduanxue, 2021
目的探索CRMP2衍生的TAT-CBD3多肽对AD大鼠神经元的保护作用及其机制。方法雄性Wistar大鼠随机分为假手术组(Sham)、模型组(Model)、TAT-CBD3高剂量组(10 mg/kg)以及TAT-CBD3低剂量组(3mg/kg)。制备大鼠阿尔茨海默病模型,模型成功后,尾静脉注射给药,连续给药15天,假手术组及模型组给予相同体积的生理盐水。末次给药后,Morris水迷宫进行大鼠行为学检测,HE染色检测大鼠海马CA1区神经元损伤,Western blot法检测相关蛋白表达 ...
姚远, 任晶红, 刘环宇, 纪影实
doaj  

Developments in the Role of Iron Imbalance in the Pathogenesis of Alzheimer's Disease [PDF]

open access: yes, 2022
Iron load is closely associated with the initiation and progression of Alzheimer's disease (AD) . Although age-dependent deposition of β-amyloid (A β) in senile plaques (SPs) , and neurofibrillary tangles (NFTs) formed by accumulation ...
GUO Shuang, CHEN Fengyan, YIN Xiang, WANG Lu, GUO Xuefeng, YU Qiming, ZOU Zhenyou, SHU Wei
core   +1 more source

干细胞外泌体在阿尔茨海默病发病机制中的作用

open access: yesZhongguo shiyan zhenduanxue, 2021
1细胞凋亡在阿尔茨海默病(AD)中的作用AD是一种常见的神经系统退行性疾病,其病理特征为β-淀粉样蛋白(Aβ)沉积,Tau蛋白高度磷酸化形成的神经纤维缠结(NFTs),以及大量神经元死亡导致大脑功能调控紊乱,从而出现严重的记忆认知障碍[1]。由于AD的具体发病机制尚不明确,目前临床上并没有成熟有效的治疗手段或者药物。
曾琳琳, 付学奇
doaj  

伴有PAXIP1和NOS3基因突变的额颞叶痴呆1例

open access: yesZhongguo shiyan zhenduanxue, 2021
额颞叶痴呆(FTD)是一组以进行性额颞叶变性(FTLD)为共同病理特征的临床综合征,发病率每年约为1.6-4.1/10万,性别无差异。在65岁以下人群中,FTD是仅次于阿尔茨海默病的第二常见痴呆。FTD是一种异质性疾病,存在不同的临床表型及神经病理类型,临床上往往以明显的人格、行为改变和语言障碍为特征,可以合并运动神经元病[1]。
王瑞, 张雷, 赵修琦, 南善姬
doaj  

Home - About - Disclaimer - Privacy